Loxo Oncology (Loxo Oncology) Long-Term Debt : $0.0 Mil (As of Sep. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Loxo Oncology Long-Term Debt?

Loxo Oncology's Long-Term Debt for the quarter that ended in Sep. 2018 was $0.0 Mil.

Loxo Oncology Long-Term Debt Historical Data

The historical data trend for Loxo Oncology's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Loxo Oncology Long-Term Debt Chart

Loxo Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Long-Term Debt

Loxo Oncology Quarterly Data
	Sep13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Loxo Oncology (NAS:LOXO) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Loxo Oncology Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Loxo Oncology's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Loxo Oncology (Loxo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Loxo Oncology Inc (NAS:LOXO) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.loxooncology.com

Loxo Oncology Inc develops medicines for patients with genetically defined cancers. Its approach is based on the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building inhibitors against single targets in the cancer cell. Its pipeline of products includes Larotrectinib, Loxo etc.

Executives

Jennifer Burstein	officer: Senior VP of Finance	C/O LOXO ONCOLOGY, INC., ONE LANDMARK SQUARE, SUITE 1122, STAMFORD CT 06901
Keith T. Flaherty	director	55 FRUIT STREET, YAWKEY 9E, BOSTON MA 02114
Lori Anne Kunkel	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Joshua H. Bilenker	director, officer: President & CEO	C/O LOXO ONCOLOGY, INC., ONE LANDMARK SQUARE, SUITE 1122, STAMFORD CT 06901
Steve Elms	director, 10 percent owner	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Alan Fuhrman	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Andrew N Schiff	10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Dennis J Purcell	10 percent owner	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Aisling Capital Iii Lp	10 percent owner	888 Seventh Avenue, 30th Fl, New York NY 10106
Aisling Capital Partners Iii Lp	10 percent owner	AISLING CAPITAL LLC, 888 SEVENTH AVENUE 30TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iii Llc	10 percent owner	AISLING CAPITAL LLC, 888 SEVENTH AVENUE 30TH FLOOR, NEW YORK NY 10106
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp V Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022